CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 483 filers reported holding CRISPR THERAPEUTICS AG in Q1 2024. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,264 | -19.3% | 40,745 | 0.0% | 0.00% | -20.0% |
Q1 2024 | $2,807 | +9.1% | 40,745 | +1.9% | 0.01% | 0.0% |
Q4 2023 | $2,572 | +40.5% | 40,000 | 0.0% | 0.01% | +25.0% |
Q3 2023 | $1,830 | -19.8% | 40,000 | 0.0% | 0.00% | -20.0% |
Q2 2023 | $2,281 | +158.3% | 40,000 | +100.0% | 0.01% | +150.0% |
Q1 2023 | $883 | +5.0% | 20,000 | -4.0% | 0.00% | 0.0% |
Q4 2022 | $841 | -99.9% | 20,843 | +4.2% | 0.00% | -50.0% |
Q3 2022 | $1,304,000 | -54.7% | 20,000 | -56.2% | 0.00% | -50.0% |
Q2 2022 | $2,877,000 | -1.7% | 45,660 | 0.0% | 0.01% | +14.3% |
Q1 2022 | $2,926,000 | +8.4% | 45,660 | +29.9% | 0.01% | 0.0% |
Q4 2021 | $2,699,000 | -51.8% | 35,160 | -30.8% | 0.01% | -56.2% |
Q3 2021 | $5,599,000 | -17.0% | 50,810 | +13.4% | 0.02% | -20.0% |
Q2 2021 | $6,744,000 | +61.2% | 44,810 | +23.4% | 0.02% | +42.9% |
Q1 2021 | $4,183,000 | +62.5% | 36,310 | +122.6% | 0.01% | +40.0% |
Q4 2020 | $2,574,000 | +125.2% | 16,310 | +21.3% | 0.01% | +100.0% |
Q3 2020 | $1,143,000 | – | 13,450 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |